Literature DB >> 17349867

Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.

Olivier Guillin1, Caroline Demily, Florence Thibaut.   

Abstract

The brain-derived neurotrophic factor (BDNF) belongs to the neurotrophins family and has a role in proliferation, differentiation of neurons but also as a neurotransmitter. This neurotrophin has received much attention during the last year in regard of the pathophysiology of schizophrenia. Results of genetic studies conducted in schizophrenia support a role for BDNF in schizophrenia and in brain function associated with the disorder. The changes of BDNF observed in the brain and in the plasma of patients with schizophrenia have generated results that can be interpreted either as a hallmark of the disease or a consequence of antipsychotic drugs. Antipsychotic drugs act by blocking the dopamine transmission at the dopamine D2-like receptors. BDNF controls the expression of one of these D2-like receptors, the dopamine D3 receptor. This raises the hypothesis of a link between cortical area, via BDNF, and the dopamine neurotransmission pathway in schizophrenia and its treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349867     DOI: 10.1016/S0074-7742(06)78012-6

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  18 in total

1.  Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.

Authors:  Francesco Matrisciano; Patricia Tueting; Stefania Maccari; Ferdinando Nicoletti; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

2.  Physical Exercise for Treatment of Mood Disorders: A Critical Review.

Authors:  C M Hearing; W C Chang; K L Szuhany; T Deckersbach; A A Nierenberg; L G Sylvia
Journal:  Curr Behav Neurosci Rep       Date:  2016-10-14

Review 3.  Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia.

Authors:  Isabel Maurus; Alkomiet Hasan; Astrid Röh; Shun Takahashi; Boris Rauchmann; Daniel Keeser; Berend Malchow; Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-05-21       Impact factor: 5.270

4.  Association study between BDNF C-281A polymorphism and paranoid schizophrenia in Polish population.

Authors:  Renata Suchanek; Aleksander Owczarek; Jan Kowalski
Journal:  J Mol Neurosci       Date:  2011-06-28       Impact factor: 3.444

5.  Structural and functional impairments of polysialic acid by a mutated polysialyltransferase found in schizophrenia.

Authors:  Ryo Isomura; Ken Kitajima; Chihiro Sato
Journal:  J Biol Chem       Date:  2011-04-04       Impact factor: 5.157

6.  BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis.

Authors:  Vijay A Mittal; Andrew Smolen; Derek J Dean; Andrea L Pelletier; Jessica Lunsford-Avery; Ashley Smith
Journal:  Schizophr Res       Date:  2012-07-04       Impact factor: 4.939

7.  BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory.

Authors:  R Nieto; M Kukuljan; H Silva
Journal:  Front Psychiatry       Date:  2013-06-17       Impact factor: 4.157

8.  A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia.

Authors:  Milawaty Nurjono; Jimmy Lee; Siow-Ann Chong
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

9.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13

Review 10.  Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update.

Authors:  Gerburg Keilhoff; Paolo Fusar-Poli; Axel Becker
Journal:  Neural Plast       Date:  2012-10-24       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.